Although each tested AML cell line harbored various types of genetic abnormalities such as MLL-AF9 or FLT3-ITD translocation, TAS4464 treatments decreased cell viability, which was accompanied by cell death in all evaluated AML cell lines (Fig. 1A). Here, FLT3 is linked to acute myeloid leukemia.